1Itoh M,Takahashi T,Sakaguchi N,et al.Thymus and autoimmunity:production of CD25^+ CD4^+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.J Immunol,1999; 162:5317 - 5326
2Baecher-Allan C,Brown JA,Freeman GJ,et al.CD4^+ CD25high regulatory cells in human peripheral blood.J Immunol,2001; 167:1245 - 1253
3Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol,1995; 155:1151 -1164
4Seo N,Hayakawa S,Takigawa M,et al.Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4^+ Tregulatory cells and systemic collapse of antitumour immunity.Immunology,2001 ;103:449 -457
5Horwitz DA,Zheng SG,Gray JD.The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4^+CD25^+ and CD8^+ regulatory T cell subsets.J Leukoc Biol,2003;74:471 -478
6Piccirillo CA,Shevach EM.Cutting edge:control of CD8^+ T cell activation by CD4^+ CD25^+ immunoregulatory cells.J Immunol,2001 ;167:1137 - 1140
8Bopp T,Palmetshofer A,Serfling E,et al.NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4^+ T lymphocytes by CD4^+ CD25^+ regulatory T cells.J Exp Med,2005; 201:181 -187
9Baecher-Allan C,Brown JA,Freeman GJ,et al.CD4^+ CD25^+ Regulatory T cells from human peripheral blood express very high levels of CD25 ex vivo.Novaritis Found Symp.2003,252:67 -88; dicussion 88 - 91,106 - 114
10Sasada T,Kimura M,Yoshida Y,et al.CD4^+ CD25^+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression.Cancer,2003; 98:1089 - 1099
6Gattinoni L,Powell DJ Tr,Rosenberg SA,et al.Adoptive immunotherapy for cancer:building on success.Nat Rev Immunol.2006;6(5):383-393.
7Williams LM,Rudensky AY.Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.Nat Immunol.2007;8(3):277-284.
8Tesniere A,Panaretakis T,Kepp O,Apetoh L,Ghiringhelli F,Zitvogel L,Kroemer G.Molecular characteristics of immunogenic cancer cell death.Cell Death Differ.《 2008;15(1):3-12.
9Rescigno M,Avogadri F,Curigliano G.Challenges and prospects of immunotherapy as cancer treatment.Biochim Biophys Aeta.2007;1776(1):108-123.
10McKee MD,Roszkowski JJ,Nishimura MI.T cell avidity and tumor recognition:implications and therapeutic strategies.J Transl Med.2005;3:35.
